Literature DB >> 28301790

Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data.

Hammad Ali1, Hamish McManus2, Catherine C O'Connor3, Denton Callander2, Marlene Kong2, Simon Graham4, Dina Saulo2, Christopher K Fairley5, David G Regan2, Andrew Grulich2, Nicola Low6, Rebecca J Guy2, Basil Donovan2.   

Abstract

OBJECTIVES: To examine the impact of the national human papillomavirus (HPV) vaccination program (available to girls and women [12-26 years] since 2007 and to boys [12-15 years] since 2013) on the number of diagnoses of genital warts in Australian Aboriginal and Torres Strait Islander (Indigenous) people. DESIGN, SETTING, PARTICIPANTS: Analysis of routinely collected data from patients attending 39 sexual health clinics (SHCs) in the Genital Warts Surveillance Network for the first time.Major outcome: The average annual proportion of Indigenous and non-Indigenous SHC patients diagnosed with genital warts during the pre-vaccination (2004-2007) and vaccination periods (2008-2014), stratified by age group and sex.
RESULTS: 7.3% of the 215 599 Australian-born patients with known Indigenous status and seen for the first time at participating SHCs during 2004-2014 were Indigenous Australians. The average proportion of female Indigenous patients diagnosed with warts was lower during the vaccination period than during the pre-vaccination period (in those under 21, summary rate ratio [SRR], 0.12; 95% CI, 0.07-0.21; P < 0.001); in 21-30-year olds: SRR, 0.41; 95% CI, 0.27-0.61; P < 0.001); there was no significant difference for women over 30 (SRR, 0.84; 95% CI, 0.51-1.36; P = 0.47). The proportion of male Indigenous heterosexual SHC patients under 21 diagnosed with warts was also lower during the vaccination period (SRR, 0.25; 95% CI, 0.12-0.49; P < 0.001), with no significant changes among older Indigenous men over 30.
CONCLUSIONS: There were marked declines in the proportions of diagnoses of genital warts in young Indigenous women and men attending SHCs after the introduction of the HPV vaccination program. If high levels of HPV vaccine coverage are sustained, HPV-related cancer rates should also decline.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28301790     DOI: 10.5694/mja16.00597

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  11 in total

1.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

2.  Human papillomavirus vaccine acceptability among healthcare workers, parents, and adolescent pupils: a pilot study in public health centers of Bali, Indonesia.

Authors:  Tantut Susanto; Erwin Nur Rif'ah; Latifa Aini Susumaningrum; Ira Rahmawati; Rismawan Adi Yunanto; Ni Luh Putu Evayanti; Putu Ayu Sani Utami
Journal:  Germs       Date:  2020-09-01

3.  A comprehensive framework for considering additional unintended consequences in economic evaluation.

Authors:  Liv Nymark; Anna Vassall
Journal:  Cost Eff Resour Alloc       Date:  2020-08-04

4.  Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention.

Authors:  Lisa Jamieson; Gail Garvey; Joanne Hedges; Amanda Mitchell; Terry Dunbar; Cathy Leane; Isaac Hill; Kate Warren; Alex Brown; Xiangqun Ju; David Roder; Richard Logan; Newell Johnson; Megan Smith; Annika Antonsson; Karen Canfell
Journal:  JMIR Res Protoc       Date:  2018-06-08

Review 5.  The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Authors:  Cyra Patel; Julia Ml Brotherton; Alexis Pillsbury; Sanjay Jayasinghe; Basil Donovan; Kristine Macartney; Helen Marshall
Journal:  Euro Surveill       Date:  2018-10

6.  Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.

Authors:  Agnieszka Denecke; Thomas Iftner; Angelika Iftner; Sebastian Riedle; Marion Ocak; Alexander Luyten; Isak Üye; Kübra Tunc; Karl Ulrich Petry
Journal:  BMC Infect Dis       Date:  2021-07-02       Impact factor: 3.090

7.  Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection.

Authors:  Heidi C Smith-Vaughan; Allen C Cheng; Sepehr N Tabrizi; Danielle F Wurzel; Jemima Beissbarth; Amanda J Leach; Peter S Morris; Michael J Binks; Paul J Torzillo; Anne B Chang; Robyn L Marsh
Journal:  Pediatr Investig       Date:  2021-06-18

8.  Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.

Authors:  S Perez; A Iñarrea; R Pérez-Tanoira; M Gil; E López-Díez; O Valenzuela; M Porto; L Alberte-Lista; M A Peteiro-Cancelo; A Treinta; R Carballo; M C Reboredo; M E Alvarez-Argüelles; M J Purriños
Journal:  Virol J       Date:  2017-11-06       Impact factor: 4.099

9.  Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.

Authors:  Dianne Egli-Gany; Anne Spaar Zographos; Joachim Diebold; Virginie Masserey Spicher; Brigitte Frey Tirri; Rolf Heusser; Joakim Dillner; Patrick Petignat; Roland Sahli; Nicola Low
Journal:  BMC Cancer       Date:  2019-01-30       Impact factor: 4.430

10.  Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians.

Authors:  Xiangqun Ju; Karen Canfell; Kirsten Howard; Gail Garvey; Joanne Hedges; Megan Smith; Lisa Jamieson
Journal:  BMC Public Health       Date:  2021-07-26       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.